Rinatabart sesutecan

Highest phase reached
Phase 2
www.ebi.ac.uk
Drug type
Antibody
www.ebi.ac.uk

Listing at source
Listed
Highest phase reached
Phase 2
www.ebi.ac.uk

Drug type
Antibody
www.ebi.ac.uk
Drug name
Rinatabart sesutecan
www.ebi.ac.uk

  • gen 1184
  • GEN-1184
  • gen1184
  • GEN1184
  • Immunoglobulin G1 [240-alanine,241-alanine], anti-(human folate receptor α) (human monoclonal PRO1184 γ1-chain, complex with human monoclonal PRO1184 κ-chain, dimer, 214′′,214′′′,226,226′,232,232′,235,235′-octakis(thioether) with N6-[39-[bis(1-deoxy-D-glucitol-1-yl)amino]-1-oxo-4,7,10,13,16,19,22,25,28,31,34,37-dodecaoxanonatriacont-1-yl]-N2-[6-(3-mercapto-2,5-dioxo-1-pyrrolidinyl)-1-oxohexyl]-L-lysyl-L-valyl-N5-(aminocarbonyl)-N-[4-[[[[[(1S,9S)-9-ethyl-5-fluoro-2,3,9,10,13,15-hexahydro-9-hydroxy-4-methyl-10,13-dioxo-1H,12H-benzo[de]pyrano[3′,4′:6,7]indolizino[1,2-b]quinolin-1-yl]amino]carbonyl]oxy]methyl]phenyl]-L-ornithinamide
  • immunoglobulin g1 240 alanine 241 alanine anti human folate receptor α human monoclonal pro1184 γ1 chain complex with human monoclonal pro1184 κ chain dimer 214 214 226 226 232 232 235 235 octakis thioether with n6 39 bis 1 deoxy d glucitol 1 yl amino 1 oxo 4 7 10 13 16 19 22 25 28 31 34 37 dodecaoxanonatriacont 1 yl n2 6 3 mercapto 2 5 dioxo 1 pyrrolidinyl 1 oxohexyl l lysyl l valyl n5 aminocarbonyl n 4 1s 9s 9 ethyl 5 fluoro 2 3 9 10 13 15 hexahydro 9 hydroxy 4 methyl 10 13 dioxo 1h 12h benzo de pyrano 3 4 6 7 indolizino 1 2 b quinolin 1 yl amino carbonyl oxy methyl phenyl l ornithinamide
  • immunoglobulin g1 kappa anti homo sapiens folr1 folate receptor 1 folate receptor alpha fr alpha adult folate binding protein fbp ovarian tumor associated antigen mov18 homo sapiens monoclonal antibody conjugated on an average of 8 cysteinyl residues to sesutecan comprising a linker and a camptothecin derivative exatecan h gamma1 heavy chain homo sapiens 1 453 vh homo sapiens ighv3 30 03 96 9 ighd ighj4 01 92 9 l123 q 118 cdr imgt 8 8 16 26 33 51 58 97 112 1 123 homo sapiens ighg1 01 g1m17 1 ch1 k120 ch3 d12 l14 g1v14 ch2 a1 3 a1 2 ch1 k120 220 124 221 hinge 1 15 222 236 ch2 l1 3 a 240 l1 2 a 241 237 346 ch3 d12 362 l14 364 347 451 chs 452 453 124 453 226 214 disulfide with l kappa light chain homo sapiens 1 214 v kappa homo sapiens igkv1 12 01 93 7 igkj4 01 91 7 cdr imgt 6 3 9 27 32 50 52 89 97 1 107 homo sapiens igkc 01 100 km3 a45 1 153 v101 191 108 214 dimer 232 232 235 235 bisdisulfide produced in a cell line from chinese hamster ovary cho cells derived from the cell line cho k1 glycoform alfa substituted at the sulfur atoms of an average of 8 l cysteinyl residues among 226 232 235 214 226 232 235 and 214 with radical group 1 2r 3r 4r 5s 52s 1 2 3 4 5 pentahydroxy 52 2s 1 2s 5 carbamoylamino 1 oxo 1 3 1s 9s 9 ethyl 5 fluoro 9 hydroxy 4 methyl 10 13 dioxo 2 3 9 10 13 15 hexahydro1h 12hbenzo de pyrano 3 4 6 7 indolizino 1 2 b quinolin 1 yl carbamoyl oxy methyl anilino pentan 2 yl amino 3 methyl 1 oxobutan 2 yl carbamoyl 7 2s 3r 4r 5r 2 3 4 5 6 pentahydroxyhexyl 46 54 dioxo10 13 16 19 22 25 28 31 34 37 40 43 dodecaoxa 7 47 53 triazanonapentacontan 59 yl 2 5 dioxopyrrolidin 3 yl sesutecan
  • immunoglobulin G1-kappa, anti-[Homo sapiens FOLR1 (folate receptor 1, folate receptor alpha, FR-alpha, adult folate-binding protein, FBP, ovarian tumor-associated antigen MOv18)], Homo sapiens monoclonal antibody, conjugated on an average of 8 cysteinyl residues to sesutecan, comprising a linker and a camptothecin derivative (exatecan); H-gamma1 heavy chain Homo sapiens (1-453) [VH (Homo sapiens IGHV3-30*03 (96.9%) -(IGHD) -IGHJ4*01 (92.9%) L123>Q (118), CDR-IMGT [8.8.16] (26-33.51-58.97-112)) (1-123) -Homo sapiens IGHG1*01, G1m17,1 CH1 K120, CH3 D12, L14, G1v14 CH2 A1.3, A1.2 (CH1 K120 (220) (124-221), hinge 1-15 (222-236), CH2 L1.3>A (240), L1.2>A (241) (237-346), CH3 D12 (362), L14 (364) (347-451), CHS (452-453)) (124-453)], (226-214')-disulfide with L-kappa light chain Homo sapiens (1'-214') [V-KAPPA (Homo sapiens IGKV1-12*01 (93.7%) -IGKJ4*01 (91.7%), CDR-IMGT [6.3.9] (27'-32'.50'-52'.89'-97')) (1'-107') -Homo sapiens IGKC*01 (100%), Km3 A45.1 (153'), V101 (191') (108'-214')]; dimer (232-232'':235-235'')-bisdisulfide, produced in a cell line from Chinese hamster ovary (CHO) cells, derived from the cell line CHO-K1, glycoform alfa; substituted at the sulfur atoms of an average of 8 L-cysteinyl residues among 226, 232, 235, 214', 226'', 232'', 235'' and 214''' with radical group 1-[(2R,3R,4R,5S,52S)-1,2,3,4,5-pentahydroxy-52-{[(2S)-1-{[(2S)-5-carbamoylamino-1-oxo-1-{3-[({[(1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro1H,12Hbenzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinolin-1-yl]carbamoyl}oxy)methyl]anilino}pentan-2-yl]amino}-3-methyl-1-oxobutan-2-yl]carbamoyl}-7-[(2S,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl]-46,54-dioxo10,13,16,19,22,25,28,31,34,37,40,43-dodecaoxa-7,47,53-triazanonapentacontan-59-yl]-2,5-dioxopyrrolidin-3-yl (sesutecan)
  • pro 1184
  • PRO-1184
  • pro1184
  • PRO1184
  • rina s
  • Rina-S
  • rinatabart sesutecan
  • Rinatabart sesutecan
  • RINATABART SESUTECAN [USAN]
  • Rinatabart sesutecan [WHO-DD]
  • rinatabart sesutecan usan
  • rinatabart sesutecan who dd

CAS registry numbers
  • 2853518-95-1
ChEMBL ID
CHEMBL6068169
www.ebi.ac.uk
FDA ingredient codes (UNII)
  • C56LJ7JC3W

First in class
No
Orphan designation
No

Pharmacology name
rinatabart sesutecan
Type
Antibody
Drug name stem
-bart; -tecan

Mechanisms of action

  • Action
    Binding
    Action type
    Binding
    Target
    folate receptor alpha
    Gene symbol
    FOLR1
    Protein identifier
    P15328

Investigated indications

  • Condition
    Neoplasms
    Highest recorded phase
    2
    Condition identifier
    EFO:0000616
    Subject identifier
    D009369

  • Condition identifier
    EFO_0000616
  • Condition identifier
    MONDO_0005065
    Highest recorded phase
    1
  • Condition identifier
    MONDO_0005070
  • Condition identifier
    MONDO_0005233
    Highest recorded phase
    2
  • Condition identifier
    MONDO_0007254
    Highest recorded phase
    1
  • Condition identifier
    MONDO_0008170
    Highest recorded phase
    3
  • Condition identifier
    MONDO_0011962
    Highest recorded phase
    3

Prodrug
No
Chirality
Single enantiomer
Inorganic
No
Natural product
No

  • Component
    Heavy chain
    Type
    Protein
    Sequence
    EVQLLESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRANSKNTLYLQMNSLRAEDTAVYYCARPRAYYGAYGSSFDYWGQGTQVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
  • Component
    Light chain
    Type
    Protein
    Sequence
    EIVMTQSPSSVSASVGDRVAITCRASQGISSWLAWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPLTFGGGTKVDIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
  • Component
    Disulfide bridges
    Sequence
    22-96 $ 22''-96'' $ 23'-88' $ 23'''-88''' $ 134'-194' $ 134'''-194''' $ 150-206 $ 150''-206'' $ 226-214' $ 226''-214''' $ 232-232'' $ 235-235'' $ 267-327 $ 267''-327'' $ 373-431 $ 373''-431''
  • Component
    Glycosylation sites (N)
    Sequence
    303 $ 303''

Related records

Trials (8)

In development for (1)